17 related articles for article (PubMed ID: 38677092)
1. Gustave Roussy Immune Score (GRIm-Score) as a Prognostic and Predictive Score in Metastatic Colorectal Cancer.
Cotan H; Iaciu C; Radu E; Niculae T; Rosu OA; Nitipir C
Cureus; 2024 Apr; 16(4):e58935. PubMed ID: 38800241
[TBL] [Abstract][Full Text] [Related]
2. Development and Validation of a Prognostic Score for Hepatocellular Carcinoma Patients in Immune Checkpoint Inhibitors Therapies: The Hepatocellular Carcinoma Modified Gustave Roussy Immune Score.
Li Y; Pan Y; Lin X; Hou J; Hu Z; Xu L; Zhou Z; Zhang Y; Chen M; Hu D
Front Pharmacol; 2021; 12():819985. PubMed ID: 35237150
[No Abstract] [Full Text] [Related]
3. Gustave Roussy Immune Score as a Novel Prognostic Scoring System for Colorectal Cancer Patients: A Propensity Score Matching Analysis.
Tian S; Cao Y; Duan Y; Liu Q; Peng P
Front Oncol; 2021; 11():737283. PubMed ID: 34917499
[TBL] [Abstract][Full Text] [Related]
4. Association of the Advanced Lung Cancer Inflammation Index (ALI) and Gustave Roussy Immune (GRIm) score with immune checkpoint inhibitor efficacy in patients with gastrointestinal and lung cancer.
Jiang H; Li B; Wu M; Wang Q; Li Y
BMC Cancer; 2024 Apr; 24(1):428. PubMed ID: 38589844
[TBL] [Abstract][Full Text] [Related]
5. The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC-GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis.
Hatanaka T; Naganuma A; Hiraoka A; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Shimada N; Kawata K; Kosaka H; Kakizaki S; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Kumada T;
Cancer Med; 2023 Feb; 12(4):4259-4269. PubMed ID: 36156452
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of Gustave Roussy immune score in operable pancreatic adenocarcinoma.
Basoglu T; Babacan NA; Ozturk FE; Arikan R; Demircan NC; Telli TA; Ercelep O; Dane F; Yumuk PF
Indian J Cancer; 2023; 60(2):179-184. PubMed ID: 36861712
[TBL] [Abstract][Full Text] [Related]
7. Association between ascites Gustave Roussy immune score and the intratumoural microbiome in malignant ascites secondary to hepatocellular carcinoma.
ShanTian ; Guo Y; Lan Q; Li J; Hu J; Qiu M; Guo C; Dong W
Int Immunopharmacol; 2024 May; 133():112097. PubMed ID: 38677092
[TBL] [Abstract][Full Text] [Related]
8. Changes in the Gustave Roussy Immune Score as a Powerful Prognostic Marker of the Therapeutic Sensitivity of Nivolumab in Advanced Gastric Cancer: A Multicenter, Retrospective Study.
Nakazawa N; Sohda M; Ubukata Y; Kuriyama K; Kimura A; Kogure N; Hosaka H; Naganuma A; Sekiguchi M; Saito K; Ogata K; Sano A; Sakai M; Ogawa H; Shirabe K; Saeki H
Ann Surg Oncol; 2022 Nov; 29(12):7400-7406. PubMed ID: 35857197
[TBL] [Abstract][Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
